<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091416</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 057</org_study_id>
    <secondary_id>10123</secondary_id>
    <nct_id>NCT00091416</nct_id>
  </id_info>
  <brief_title>Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Safety of a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Administered to Healthy, HIV-1 Uninfected, Adult Participants Who Received DNA Plasmid Vaccine or Placebo in the HVTN 052 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine,&#xD;
      VRC-HIVADV014-00-VP, when given as a vaccine booster to HIV uninfected adults who&#xD;
      participated in HVTN 052.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The worldwide HIV epidemic highlights the importance of developing an affordable, globally&#xD;
      successful vaccine for HIV prevention. The VRC-HIVADV014-00-VP adenoviral vector vaccine used&#xD;
      in this study was developed to stimulate strong virus-specific CD8 cytotoxic T-lymphocyte&#xD;
      (CTL) responses thought to be crucial in an effective preventive HIV vaccine. The purpose of&#xD;
      this study is to determine the safety and immunogenicity of a VRC-HIVADV014-00-VP vaccine&#xD;
      boost given to healthy, HIV uninfected individuals who participated in HVTN 052, which&#xD;
      evaluated the VRC-HIVDNA009-00-VP DNA plasmid vaccine. In that study, participants received&#xD;
      either 3 injections of vaccine, 2 injections of vaccine and 1 injection of placebo, or 3&#xD;
      injections of placebo over a 2-month period.&#xD;
&#xD;
      This study will last one year. Participants will be randomly assigned to receive vaccine&#xD;
      boost or placebo by intramuscular injection. The injections will be given 6 to 9 months after&#xD;
      each participant's first HVTN 052 study injection, preferably as close to 6 months after the&#xD;
      first HVTN 052 injection as possible. After a screening visit, study visits will occur at&#xD;
      enrollment (when the injection will be given), at Week 2, and at Months 1, 3, 6, and 12.&#xD;
      Blood collection, physical exam, and medication assessment will occur at every study visit;&#xD;
      urine collection will occur at selected visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">70</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC-HIVADV014-00-VP</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously enrolled in and have completed all 3 study vaccine injections for HVTN 052&#xD;
&#xD;
          -  Understanding of vaccination procedure&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
          -  HIV uninfected&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Anti-hepatitis C virus (HCV) antibody negative, or negative for HCV PCR if the&#xD;
             anti-HCV is positive&#xD;
&#xD;
          -  Willing to use acceptable forms of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunosuppressive medications within 168 days prior to study&#xD;
&#xD;
          -  Blood products within 120 days prior to study&#xD;
&#xD;
          -  Immunoglobulin within 60 days prior to study&#xD;
&#xD;
          -  Live attenuated vaccines within 30 days prior to study&#xD;
&#xD;
          -  Investigational research agents within 30 days prior to study&#xD;
&#xD;
          -  Medically indicated subunit or killed vaccines within 14 days prior to study&#xD;
&#xD;
          -  Allergy shots within 30 days prior to study&#xD;
&#xD;
          -  Current anti-tuberculosis prophylaxis or therapy&#xD;
&#xD;
          -  Anaphylaxis or other serious adverse reactions to vaccines. A person who had an&#xD;
             adverse reaction to pertussis vaccine as a child is not excluded.&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Active syphilis infection&#xD;
&#xD;
          -  Unstable asthma (e.g., daily symptoms; use of oral or orally inhaled corticosteroids&#xD;
             or other treatments; emergent care, urgent care, hospitalization, or intubation during&#xD;
             the past 2 years)&#xD;
&#xD;
          -  Diabetes mellitus. A participant with past gestational diabetes is not excluded.&#xD;
&#xD;
          -  Thyroid disease, including removal of thyroid and diagnoses requiring medication. A&#xD;
             participant not requiring thyroid medication during the last year is not excluded.&#xD;
&#xD;
          -  Serious angioedema. A participant who has had an episode of angioedema over 3 years&#xD;
             prior to the study, and has not required medications for at least 2 years, is not&#xD;
             excluded.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Diagnosis of bleeding disorder&#xD;
&#xD;
          -  Malignancy, except those with a surgical excision that has a reasonable assurance of&#xD;
             sustained cure and/or is unlikely to recur during the period of the study&#xD;
&#xD;
          -  Seizure disorder requiring medication within the last 3 years&#xD;
&#xD;
          -  Absence of the spleen&#xD;
&#xD;
          -  Mental illness that would interfere with compliance with the protocol&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Peiperl, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Francisco Department of Public Health / University of California - San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julie McElrath, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center / University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205-1901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Community Health Clinical Research Site (FCHCRS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Univ. School of Medicine, HVTU</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-2500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HIV Prevention &amp; Treatment CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester HVTN CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miriam Hospital's HVTU</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vaccine CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FHCRC/UW Vaccine CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/show/NCT00071851</url>
    <description>Click here for more information about the HVTN 052 study</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/contentfiles/HIVPreventionVaccines_FS_en.pdf</url>
    <description>Click here for more information on HIV preventive vaccines</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1527</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>Gómez-Román VR, Robert-Guroff M. Adenoviruses as vectors for HIV vaccines. AIDS Rev. 2003 Jul-Sep;5(3):178-85. Review.</citation>
    <PMID>14598567</PMID>
  </reference>
  <reference>
    <citation>McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther. 2002 Feb;4(1):23-7. Review.</citation>
    <PMID>11883691</PMID>
  </reference>
  <reference>
    <citation>Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, Ertl HC. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol. 2003 Dec 15;171(12):6774-9.</citation>
    <PMID>14662882</PMID>
  </reference>
  <reference>
    <citation>Shiver JW, Emini EA. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med. 2004;55:355-72. Review.</citation>
    <PMID>14746526</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 8, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Seronegativity</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

